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Clinical Infectious Diseases
SUPPLEMENT ARTICLE
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as a Predictor of Pneumonia—Haemophilus influenzae,
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Background. There is limited information on the association between colonization density of upper respiratory tract colonizers
and pathogen-specific pneumonia. We assessed this association for Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus
aureus, and Pneumocystis jirovecii.
Methods. In 7 low- and middle-income countries, nasopharyngeal/oropharyngeal swabs from children with severe pneumonia
and age-frequency matched community controls were tested using quantitative polymerase chain reaction (PCR). Differences in
median colonization density were evaluated using the Wilcoxon rank-sum test. Density cutoffs were determined using receiver operating characteristic curves. Cases with a pathogen identified from lung aspirate culture or PCR, pleural fluid culture or PCR, blood
culture, and immunofluorescence for P. jirovecii defined microbiologically confirmed cases for the given pathogens.
Results. Higher densities of H. influenzae were observed in both microbiologically confirmed cases and chest radiograph
(CXR)–positive cases compared to controls. Staphylococcus aureus and P. jirovecii had higher densities in CXR-positive cases vs
controls. A 5.9 log10 copies/mL density cutoff for H. influenzae yielded 86% sensitivity and 77% specificity for detecting microbiologically confirmed cases; however, densities overlapped between cases and controls and positive predictive values were poor (<3%).
Informative density cutoffs were not found for S. aureus and M. catarrhalis, and a lack of confirmed case data limited the cutoff
identification for P. jirovecii.
Conclusions. There is evidence for an association between H. influenzae colonization density and H. influenzae–confirmed pneumonia in children; the association may be particularly informative in epidemiologic studies. Colonization densities of M. catarrhalis,
S. aureus, and P. jirovecii are unlikely to be of diagnostic value in clinical settings.
Keywords. pneumonia; colonization density; PERCH.
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Many pneumonia pathogens can also be upper respiratory
tract (URT) colonizers, including Streptococcus pneumoniae,
Haemophilus influenzae, Staphylococcus aureus, Moraxella
catarrhalis, and Pneumocystis jirovecii [1–6]. Obtaining specimens from the site of infection remains challenging, as direct
lung aspiration is rarely done, and blood cultures are insensitive and often unavailable in areas of highest pneumonia
burden [7, 8]. In many settings, the high frequency of URT
colonization with these potential pathogens in healthy children undermines the application of qualitative diagnostic
tests, such as polymerase chain reaction (PCR), to ascribe etiology [9].
Previous studies have suggested that children with pneumonia may have higher pathogen density in the URT compared to
children without pneumonia, though there is heterogeneity by
study and pathogen [1, 4, 10–19]. We set out to determine if density of URT colonizers predicted pathogen-specific infections
among pneumonia cases in the Pneumonia Etiology Research
for Child Health (PERCH) study. Provided differences in densities between cases and controls, we evaluated whether pathogen
densities offer any value in pneumonia diagnostic algorithms, or
provide information beyond presence or absence of positivity
alone in analytic models such as the PERCH integrated analysis
[20]. The density evaluation for S. pneumoniae is reported elsewhere [21].
METHODS

The PERCH study is a multicountry, standardized evaluation of the etiologic agents causing severe and very severe
pneumonia among children in sites in 7 low- and middle-income countries: Dhaka and Matlab, Bangladesh; Basse, The
Gambia; Kilifi, Kenya; Bamako, Mali; Soweto, South Africa;
Nakhon Phanom and Sa Kaeo, Thailand; and Lusaka, Zambia.
Haemophilus influenzae type b vaccine was used routinely at all
sites except Thailand, while South Africa, The Gambia, Mali,
and Kenya used pneumococcal conjugate vaccine throughout
the duration of the study [22]. PERCH followed a standardized
protocol for enrollment, specimen collection, and laboratory
testing [23].
Case and Community Control Selection and Clinical Evaluation

Identification and selection of cases and controls have been
described previously [24]. In brief, we enrolled hospitalized
patients aged 1– 59 months with World Health Organization
(WHO)–defined severe or very severe pneumonia and age-frequency matched community controls. Severe pneumonia was
defined as having cough or difficulty breathing and lower chest
wall indrawing; very severe pneumonia was defined as cough or
difficulty breathing and at least 1 of the following: central cyanosis, difficulty breastfeeding/drinking, vomiting everything,
convulsions, lethargy, unconsciousness, or head nodding [25].

Within this case definition we further defined radiographic
pneumonia as consolidation or any other infiltrate on chest radiograph (CXR positive) as interpreted by a panel of trained CXR
readers [26, 27]. Microbiologically confirmed cases were those
with identification of the respective pathogen by PCR from lung
aspirate or pleural fluid; bacterial culture from lung aspirate, pleural fluid, or blood; or P. jirovecii by induced sputum, pleural fluid,
or lung aspirate immunofluorescence or toluidine blue staining
[28]. Antibiotic pretreatment was defined by having either positive serum bioassay or clinician report of antibiotics administered
prior to specimen collection on the day of admission.
Specimen Collection

A flocked nasopharyngeal (NP) swab (flexible minitip, Copan)
and a rayon oropharyngeal (OP) swab (Fisher Scientific), transported in universal transport media (Copan) and processed
within 24 hours of collection were used for URT pathogen
detection by PCR. Blood was collected for culture. Pleural fluid
specimens were collected as clinically indicated. Lung aspirates
were collected from a subset of cases in The Gambia, South
Africa, Mali, and Bangladesh.
Laboratory Testing

PERCH employed conventional and molecular diagnostic techniques for the identification of potential pathogens, as described
elsewhere [8, 28–31]. In brief, total nucleic acid extraction was
performed on respiratory specimens using the NucliSens easyMAG system (bioMérieux, Marcy l’Etoile, France). Four hundred microliters of each respiratory specimen was eluted to a
final volume of 60–110 μL nucleic acid.
Respiratory specimens (including lung aspirate and pleural
fluid specimens) were evaluated using the Fast Track Diagnostics
Respiratory Pathogens 33 test (FTD Resp-33) (Fast-track
Diagnostics, Sliema, Malta), a 33-target, 8-multiplex real-time
quantitative PCR platform for the detection of selected viruses
and the following bacteria and fungi: P. jirovecii; Mycoplasma
pneumoniae; Chlamydophila pneumoniae; S. pneumoniae; H.
influenzae type b; H. influenzae species; S. aureus; M. catarrhalis; Bordetella pertussis; Klebsiella pneumoniae; and Salmonella
species. Standard curves for quantification were generated using
10-fold serial dilutions of plasmid standards provided by FTD
approximately every 3 months and were used to calculate pathogen density (log10 copies/mL) from the sample cycle threshold
values; standards were only available for the linear range of detection of the assay from 4.0 to 8.0 log10 copies/mL. Additionally,
induced sputum, pleural fluid, and lung aspirate specimens were
tested for P. jirovecii by immunofluorescence (South Africa) and
toluidine blue staining (Zambia).
Blood cultures were incubated using automated systems
(BacT/ALERT in South Africa, Thailand, and Bangladesh;
BACTEC at all other sites). Organisms were identified according to standard microbiological methods.
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Statistical Analysis

We made comparisons between community controls and both
microbiologically confirmed pneumonia cases and radiographic pneumonia cases. Microbiologically confirmed cases
were not restricted to children with abnormal findings on CXR
in order to include children who died before a radiograph was
taken or had not developed a positive finding at time of initial
radiograph. Human immunodeficiency virus (HIV)–infected
cases were included in a supplemental analysis for P. jirovecii
but excluded from all other analyses.
Among children positive for each organism, mean and
median colonization densities were compared using Wilcoxon
rank-sum tests. Potential covariates of colonization density
were evaluated, including site, age, sex, vaccination status, and
prior antibiotic administration [32]. Total bacterial load (across
all bacteria tested for by FTD Resp-33) was compared between
cases and controls, in addition to proportional pathogen densities comparing proportional contributions of a given organism to the total bacterial load. Receiver operating characteristic
(ROC) curves and the corresponding area under the curve
(AUC) were generated to investigate the performance of absolute density in determining case status among microbiologically
confirmed cases and community controls including children
without detection of the given pathogen in the URT by PCR, and
also between radiographic pneumonia cases and community
Table 1.

controls positive for each organism in the URT by PCR. The
Youden index was calculated to determine the best-performing
cutoffs to differentiate cases and community controls [33]. To
guard against bias in the estimates of sensitivity due to having
a small number of confirmed cases for each potential pathogen, the Youden index was calculated using leave-one-out
cross-validation when sample sizes were sufficient [34]. Positive
and negative predictive values associated with each cutoff were
calculated comparing microbiologically confirmed cases as the
gold standard against all HIV-uninfected cases.
All analyses were performed using SAS software version 9.4
(SAS Institute, Cary, North Carolina) and R Statistical Software
3.2.1 (R Foundation for Statistical Computing, Vienna, Austria).
P values are 2 sided.
Ethical Considerations

The PERCH study protocol was approved by the institutional
review board or ethical review committee at each of the study
site institutions and at the Johns Hopkins Bloomberg School of
Public Health. Parents or guardians of all participants provided
written informed consent.
RESULTS

Of the 4232 cases enrolled in the PERCH study, 4139 cases had
available NP/OP PCR results; of those, 239 additional cases

Characteristics of Children Included in Analysis of Quantificationa
Microbiologically Confirmed Casesb
(n = 52)

CXR-Positive Casesc
(n = 1700)

Controls
(n = 4986)

Kenya

4 (7.7)

278 (16.4)

855 (17.1)

The Gambia

8 (15.4)

267 (15.7)

624 (12.5)

Mali

14 (26.9)

229 (13.5)

724 (14.5)

Zambia

11 (21.2)

185 (10.9)

535 (10.7)

South Africa

13 (25.0)

425 (25.0)

823 (16.5)

Thailand

2 (3.8)

97 (5.7)

657 (13.2)

Bangladesh

0 (0)

Characteristic
Site

Age

219 (12.8)

768 (15.4)
1555 (31.2)

1-5 mo

24 (46.2)

667 (39.2)

6-11 mo

11 (21.2)

409 (24.1)

1187 (23.8)

12-23 mo

11 (21.2)

414 (24.4)

1235 (24.8)

6 (11.5)

210 (12.4)

1009 (20.2)

Sex

24-59 mo
Female

32 (61.5)

736 (43.3)

2477 (49.7)

Antibioticsd

Prior to NP/OP swab collection

22 (42.3)

791 (46.5)

84 (1.7)

No. of bacteria detectede

0

…

75 (4.4)

141 (2.8)

1

2 (3.8)

197 (11.6)

486 (9.7)

2

9 (17.3)

376 (22.1)

1141 (22.9)

≥3

40 (76.9)

1033 (60.8)

3195 (64.1)

P value <.05 for case-control group comparisons of overall site, overall age, sex, prior antibiotics, and number of bacteria detected, obtained from χ2 test.
Data are presented as No. (%).
Abbreviations: CXR, chest radiograph; NP/OP, nasopharyngeal/oropharyngeal.
a

Children with available NP/OP polymerase chain reaction results.

b

Microbiologically confirmed for Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, or Pneumocystis jirovecii.

c

CXR positive defined as having radiographic evidence of pneumonia (consolidation and/or other infiltrate), excluding microbiologically confirmed cases of H. influenzae, M. catarrhalis,
S. aureus, or P. jirovecii.
d
Administered antibiotics at the study facility prior to the collection of specimens (cases only), positive serum bioassay (cases and controls), received antibiotics at a referral facility (cases
only), or received routine cotrimoxazole prophylaxis (cases and controls).
e

Including Bordetella pertussis, Chlamydophila pneumoniae, H. influenzae, M. catarrhalis, Mycoplasma pneumoniae, P. jirovecii, S. aureus, Salmonella species, and Streptococcus pneumoniae.
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were excluded for being HIV infected, resulting in 3900 cases.
Among the 3900 cases, 52 (1.3%) were microbiologically confirmed for at least 1 organism of interest, 1733 (44.4%) had an
abnormal CXR, and 1700 (43.6%) had an abnormal CXR without microbiologic confirmation of H. influenzae, M. catarrhalis,
S. aureus, or P. jirovecii (Table 1). Site sample sizes for CXRpositive cases varied from 425 cases in South Africa to 97 cases
in Thailand. From 5118 enrolled HIV-negative controls, 4986
(97.4%) had available NP/OP PCR results. Compared to controls, cases tended to be younger and were more likely to have
had antibiotics prior to their NP/OP sample collection.
Prevalence and Density Comparisons Between Microbiologically
Confirmed Cases, Radiographic Pneumonia Cases, and Community Controls

All 21 cases with microbiologically confirmed H. influenzae (8
type b, 9 nontypeable, 2 type a, 2 unknown) were NP/OP positive for H. influenzae. Among the 21 cases, 14 (66.7%) were CXR
positive. Six confirmed M. catarrhalis cases were NP/OP positive, among which 4 (66.7%) were CXR positive. Fifteen confirmed S. aureus cases were NP/OP positive, among which 10
(66.7%) were CXR positive. One confirmed P. jirovecii case was
NP/OP positive and was also CXR positive. Only H. influenzae
was found at significantly higher median densities in microbiologically confirmed cases compared to controls (Table 2).
Comparing non–microbiologically confirmed CXR-positive
cases to controls, H. influenzae was more commonly detected in the
NP/OP of cases vs controls (57.3% vs 51.5%, P < .001). Prevalence
was similar between CXR-positive cases and controls for S. aureus
and P. jirovecii. Moraxella catarrhalis detection was more common
among controls than CXR-positive cases, even after adjusting for

site and prior antibiotics (65.8% vs 74.3%, P ≤ .001). Median density (log10 copies/mL) was higher in CXR-positive cases compared
to controls for H. influenzae, S. aureus, and P. jirovecii, while M.
catarrhalis median density was similar in CXR-positive cases and
controls. For all organisms, there was substantial overlap of the distribution of densities between microbiologically confirmed cases,
CXR-positive cases, and controls (Figure 1).
Though densities varied by site, trends between microbiologically confirmed cases, CXR-positive cases, and controls
remained and were consistent across age categories, WHOdefined severity categories, and sex (Supplementary Figure 2).
Prior antibiotic use was associated with a lower density for
H. influenzae (6.15 vs 5.64 log10 copies/mL) and M. catarrhalis (5.77 vs 5.21 log10 copies/mL) among CXR-positive cases
(Supplementary Figure 3). There were similar rates of antibiotic
use prior to NP/OP specimen collection between microbiologically confirmed cases and nonconfirmed CXR-positive cases.
HIV-infected, CXR-positive cases had a higher median density
compared to HIV-negative, CXR-positive cases for P. jirovecii
(5.03 vs 3.78 log10 copies/mL) (Supplementary Figure 4).
Total and Proportional Bacterial Density

Total bacterial density across all bacterial targets from our PCR
panel was similar among consolidated pneumonia cases (5.90
log10 copies/mL), CXR-positive cases (5.81 log10 copies/mL), and
controls (5.75 log10 copies/mL), and also similar among CXRpositive cases across age groups, adjusting for prior antibiotic
use and site. Evaluating whether the proportion of total bacterial
density attributable to specific organisms differed between case
and control groups, median relative proportions of H. influenzae

Table 2. Detection Prevalence and Median Pathogen Density (Copies/mL) From Nasopharyngeal/Oropharyngeal Swabs for Microbiologically Confirmed
Cases, Non–Microbiologically Confirmed Radiographic Pneumonia Cases, Cases Microbiologically Confirmed for Another Pathogen, and Controls—
All Sites

Colonizer
Haemophilus
influenzae

Measure
NP/OP+, No. (%)d
Median density (IQR)e

Moraxella
catarrhalis

NP/OP+, No. (%)d
Median density (IQR)f

Pneumocystis
jirovecii

NP/OP+, No. (%)d
Median density (IQR)f

Staphylococcus
aureus

NP/OP+, No. (%)d
Median density (IQR)f

A. Confirmed
Casesa
21/21 (100)
6.77 (6.00–7.12)
6/7 (85.7)
6.01 (5.00–6.73)
1/2 (50.0)
4.01 (NA)
15/23 (65.2)
4.87 (3.87–5.64)

B. CXR-Positive
Cases (n = 1657)
949 (57.3)
5.90 (5.00–6.66)
1091 (65.8)
5.50 (4.65–6.26)
149 (9.0)
3.92 (3.08–4.73)
342 (20.6)
4.48 (3.43–5.53)

C. Cases Confirmed for
Other Pathogenb
76/121 (62.8)
6.39 (5.53–7.08)
92/135 (68.1)
6.15 (5.09–6.78)
10/140 (7.1)
4.00 (2.14–5.95)
29/119 (24.5)
5.14 (4.46–5.85)

D. All Controls
(n = 4986)

Difference in Median
Densities, P Valuec
A vs C

A vs D

B vs D

.19

<.001

<.001

.88

.44

.07

…

.44

<.001

.43

.13

.05

2562 (51.5)
5.71 (4.89–6.35)
3694 (74.3)
5.59 (4.87–6.20)
382 (7.7)
3.56 (3.02–4.10)
940 (18.9)
4.29 (3.42–5.17)

Abbreviations: CXR, chest radiograph; IQR, interquartile range; NA, not applicable; NP/OP, nasopharyngeal/oropharyngeal.
a

Detection of relevant pathogen from blood culture, lung aspirate culture/polymerase chain reaction (PCR), pleural fluid culture/PCR, pneumocystis immunofluorescence or staining.

b

Microbiologically confirmed case for any other bacteria or virus.

c

Comparing median densities using Wilcoxon rank-sum test.

d

No. (%) positive in the NP/OP for organism among those with available results for that target.

e

Log10 copies/mL, among all confirmed case positives including NP/OP PCR negatives counted as zero densities.

f

Among those positive on NP/OP PCR.
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Figure 1. Median density in the nasopharynx/oropharynx (NP/OP) among microbiologically confirmed cases, radiographic pneumonia (chest radiograph positive [CXR+])
casesa, and controls, restricted to participants testing NP/OP positive for the given pathogen. Horizontal lines through boxes indicate group medians. Boxes extend to the 25th
and 75th percentiles. Whiskers extend to minimum and maximum. aDefined as having radiographic evidence of pneumonia (consolidation and/or other infiltrate), excluding
confirmed cases.

tended to be higher in H. influenzae–confirmed cases (41.6%)
and CXR-positive cases (7.2%) compared with controls (1.2%).
Conversely, median proportional densities of M. catarrhalis
were higher in controls compared to CXR-positive cases (14.3%
vs 5.0%). Among 100 randomly selected controls, 24% had
M. catarrhalis–dominated proportional densities (≥50%) compared with 14%–16% of non–M. catarrhalis confirmed cases
(Supplementary Figure 6). However, there was substantial overlap in the range of proportional densities between microbiologically confirmed cases, CXR-positive cases, and controls.
Determination of Density Cutoffs

Using density in log10 copies/mL in microbiologically confirmed
cases compared to controls, the ROC curve best-performing
cutoff of 5.9 log10 copies/mL was identified for H. influenzae
with a sensitivity of 86% and specificity of 77% (Figure 2 and

Table 3). Though the S. aureus cutoff (3.0 log10 copies/mL) was
moderately sensitive and specific, the S. aureus cutoff did not
significantly improve sensitivity and specificity over qualitative
analysis using simply presence or absence of specific organisms.
Given the limited numbers of NP/OP-positive microbiologically confirmed P. jirovecii (n = 1) and M. catarrhalis (n = 6)
cases, we explored the use of NP/OP positive, CXR-positive
cases and controls to identify potential cutoffs for P. jirovecii
(4.0 log10 copies/mL) and M. catarrhalis (5.0 log10 copies/mL)
(Supplementary Figure 5). Densities among the limited number
of microbiologically confirmed cases were consistent with these
cutoffs, as 5 of 6 microbiologically confirmed M. catarrhalis
cases were above the thresholds. The P. jirovecii cutoff demonstrated 48% sensitivity and 72% specificity for identifying
P. jirovecii–positive CXR-positive cases (AUC = 0.58), among
cases and controls positive for P. jirovecii (98% specificity

Table 3. Receiver Operating Characteristic Curve Nasopharyngeal/Oropharyngeal Cutoffsa for Determining Case Status and Corresponding Area Under
the Curve, Positive Proportion in Cases, and Negative Proportion in Controls by Pathogen
NP/OP-Positive, CXR-Positive Casesb vs Controls

Confirmed Cases vs Controls
Best-Performing
Cutoff (Log10
Copies/mL)

AUC

Proportion of
Cases Above
Cutoff

Proportion of
Controls Below
Cutoff

Best-Performing
Cutoff (Log10
Copies/mL)

Haemophilus
influenzae

5.92

0.87

0.86

0.77

Moraxella
catarrhalis

…

…

…

Pneumocystis
jirovecii

…

…

2.97

0.6

Colonizer

Staphylococcus
aureus

AUC

Proportion of
Positive Cases
Above Cutoff

Proportion of
Positive Controls
Below Cutoff

…

…

…

…

…

4.99

0.50

0.34

0.71

…

…

4.01

0.58

0.48

0.72

0.65

0.84

…

…

…

…

Abbreviations: AUC, area under the curve; CXR, chest radiograph; NP/OP, nasopharyngeal/oropharyngeal.
a

Cutoffs for confirmed cases calculated using the Youden index for H. influenzae, and S.aureus (with cross-validation). Confirmed cases defined as any detection from blood culture, lung
aspirate culture/polymerase chain reaction (PCR), or pleural fluid culture/PCR. Cutoffs for CXR-positive cases calculated using the Youden index (with cross-validation) comparing CXR-positive
cases to controls, excluding children who were negative by NP/OP PCR.
b

Defined as having radiographic evidence of pneumonia (consolidation and/or other infiltrate).
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Figure 2.
controls.

Receiver operating characteristic (ROC) curve and Youden index analysis for Haemophilus influenzae and Staphylococcus aureus confirmed cases compared with

including negatives). Moraxella catarrhalis cutoffs did not help
differentiate CXR-positive cases from controls (AUC = 0.50).
Positive and Negative Predictive Values Using Dichotomous Positivity and
Density Cutoffs

Positive predictive values (PPVs) for identifying microbiologically confirmed cases from all cases using dichotomous URT
positivity were low and improved marginally when density cutoffs were applied to H. influenzae (1.01% to 1.75%), S. aureus
(1.81% to 2.14%), and P. jirovecii (0.89% to 1.67%), though the
PPV is limited by lack of sensitivity in identifying microbiologically confirmed cases. Conversely, negative predictive values for
identifying H. influenzae, S. aureus, and P. jirovecii microbiologically confirmed cases remained >99% for any detection in
the URT and when utilizing the density cutoff.
Clinical Characteristics Associated With Being Above Versus Below
Optimized Cutoffs

Densities above the cutoffs (compared to low densities and negatives) were associated with hypoxemia (adjusted odds ratio
[AOR], 1.22; 95% confidence interval [CI], 1.02–1.47), any
CXR abnormality (AOR, 1.23; 95% CI, 1.05–1.45), and primary
endpoint consolidation (AOR, 1.57; 95% CI, 1.28–1.92) for
H. influenzae, adjusted for site, age, sex, and prior antibiotic use.
Additionally, having a density above the cutoff was associated
with case fatality for P. jirovecii (AOR, 4.5; 95% CI, 2.6–7.5).
DISCUSSION

Colonization density of the URT with H. influenzae was significantly higher in microbiologically confirmed cases compared

with community controls. Given the high prevalence of H. influenzae as a common colonizer, the improved specificity provided
by the optimized cutoff of 5.9 log10 copies/mL helped delineate
between common colonization and H. influenzae–mediated
pneumonia. However, the overlapping density distributions
between all case and control groups, and the low PPV limit
the utility of density in individuals for clinical diagnosis. Our
findings are similar to results from a study in adult patients in
Denmark that yielded 90% sensitivity and 65% specificity using
a cutoff at 5.0 log copies/mL [17]. Another study in Vietnamese
children did not find an association between NP H. influenzae
density and radiographic pneumonia; however, findings may
have been limited by lack of a confirmed case group [12].
Colonization density of P. jirovecii may provide information toward differentiating carriage and pathogen-mediated
pneumonia, although our evaluation was limited by a lack of
microbiologically confirmed pneumocystis pneumonia (PCP)
cases. A potential cutoff at 4.0 log10 copies/mL conferred 50%
sensitivity and 72% specificity for radiographic pneumonia;
however, the proportion of radiographic pneumonia cases with
PCP-mediated pneumonia is unknown, and the PERCH process for identifying CXR abnormality may have been less sensitive for detecting radiographic features uniquely associated
with PCP. The potential density cutoff is in line with other studies that have identified cutoffs between approximately 3 and 4.5
log copies/mL using clinically confirmed PCP patients, though
we have not standardized the quantitative standards across
these different studies [14–16]. Utilizing P. jirovecii detection
from induced sputum PCR is widely accepted in clinical practice and would have expanded our sample of microbiologically
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confirmed cases [35, 36]. However, these diagnostic tests are
typically carried out when pneumocystis pneumonia is clinically suspected; findings from the PERCH study complicate
the utility of induced sputum PCR as a confirmatory diagnostic
tool in settings where nearly all cases had an induced sputum
specimen collected [37].
Previous studies have failed to identify an association between
density and pathogen-confirmed pneumonia for M. catarrhalis
and S. aureus [1]. While the optimized S. aureus cutoff was specific, the relatively high proportion of NP/OP negatives among
the microbiologically confirmed cases precludes the identification of a highly sensitive and specific cutoff. It has been
suggested that Moraxella and Corynebacterium/Dolosigranulumdominated microbiota profiles confer stability and are protective against respiratory disease, while Streptococcus- and
Haemophilus-dominated microbiota profiles enhance susceptibility to respiratory infections [38, 39]. The protective effect of
M. catarrhalis is supported by our finding of both higher prevalence, proportional density, and absolute density in controls
compared to radiographic pneumonia cases.
Though our analysis benefited from a large sample size enrolled
from multiple heterogeneous study sites and comprehensive
clinical and laboratory standardization, there were limitations.
Despite our large overall sample size, the number of microbiologically confirmed cases was limited. However, leave-one-out
cross validation and findings from comparisons of CXR-positive
cases vs controls supported findings from microbiologically confirmed cases. While we were able to evaluate co-pathogen interactions and proportional densities between a select number of
potential pathogens, a metagenomics or microbiome approach
would be better suited to understand the contribution of individual pathogens in the context of the upper respiratory tract
microbiome [40–45]. Furthermore, we were unable to establish
temporality between higher densities in the NP/OP and subsequent development of pneumonia, as infection in the lung may
lead to higher densities in the NP/OP. Longitudinal studies would
be better suited to addressing the role of colonization density on
the development of pneumonia. The study design did not control
for prior antibiotic use, which was associated with lower densities
for both H. influenzae and M. catarrhalis. However, because prior
antibiotic use was more common among cases compared to controls, the bias was toward the null for the analyses. Staphylococcus
aureus and P. jirovecii are unlikely to be significantly affected by
first-line antibiotics, which was reflected in our findings [46].
Variability of density distributions by site was also observed;
however, density trends between the microbiologically confirmed case, radiographic pneumonia case, and control groups
within a site followed the overall trends.
While we have provided cutoffs optimized for sensitivity and
specificity, the choice of a cutoff can be tailored for specific applications. Identifying a density cutoff that maximizes combined
sensitivity and specificity provides additional information from

the NP/OP specimen in the PERCH primary etiology analysis; however, the interpretation and application of these cutoffs
may not be ideal for use as either a diagnostic or screening tool
(which may prioritize specificity and sensitivity, respectively).
Moreover, the PPV using the density cutoff remained low for
H. influenzae, although the PPV was limited by poor sensitivity for identifying microbiologically confirmed cases and low
prevalence. Regardless, it is likely impossible to identify a URT
density cutoff for these colonizers that could be applied as a
clinical gold standard because the densities overlap and span
the PCR linear range in both cases and controls, precluding the
identification of clear cutoffs that would independently guide
clinical decisions.
We found evidence for the relationship between H. influenzae
colonization density and H. influenzae–mediated pneumonia
in children, and also a potential association between P. jirovecii
colonization density and pathogen-specific pneumonia. The use
of molecular diagnostics from URT specimens provides significant advantages in both sensitivity and speed over traditional
culture diagnostics, but ascribing lung infection based on detection of colonization in the URT is challenging. Compared to
using presence or absence of positivity, utilizing colonization
density improves specificity of molecular diagnostics with small
reductions in sensitivity and improves information from the
URT in the context of population-level epidemiologic studies
such as the PERCH integrated analysis, but remains suboptimal
for use as a gold standard diagnostic in clinical settings at the
individual case level.
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